NEW YORK (GenomeWeb News) — Biofortuna said today that it has received 510(k) clearance from the US Food and Drug Administration for its SSPGo HLA PCR kits.

The qualitative DNA-based kits are used to determine human leukocyte antigen alleles in low to intermediate resolution, and are designed for transplantation genotyping and identification of genes that may be associated with various genetic conditions, the UK-based company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.